This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): Budenofalk 2mg Rectal Foam (UK), budesonide foam, AJG511
Budesonide rectal foam is a formulation of budesonide, a glucocorticoid.
An oral formulation of Uceris has also been developed by Salix.
Deal Structure: Budesonide rectal foam was originally developed by Dr. Falk Pharma.
Dr. Falk and Salix
In March 2008, Dr. Falk Pharma granted Salix a license to its family of budesonide products in the United States, including the foam. Salix is required to make an upfront payment and regulatory milestone payments to Dr. Falk Pharma, with the majority contingent upon achievement of U.S. regulatory approval. In addition, Salix will pay royalties on net sales.
Dr. Falk and Biotoscana
According to Biotoscana Argentina's website, the company's pharmaceutical partners include Dr. Falk. We believe both companies have an exclusive license agreement for the commercialization of Budenofalk in Argentina.
Salix and Cosmo
In July 2014, Salix Pharmaceuticals and Cosmo Pharmaceuticals announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (Cosmo Tech), a subsidiary of Cosmo. Under the terms of the agreement, Salix will...See full deal structure in Biomedtracker
Partners: Dr. Falk Pharma GmbH Biotoscana International EA Pharma Co., Ltd. Kissei Pharmaceutical Co., Ltd
Uceris Foam News
Pink Sheet October Full Approvals
Additional information available to subscribers only: